Ticagrelor
(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-D1,2-Cyclopentanediolifluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol; AR-C 1265
Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS)
Solubility
Chloroform, DMSO, Methanol
Method for Determining Identity
Proton NMR (DMSO-d6 , CD3OD, & CDCl3) Spectroscopic and Mass Spectrometric AnalysisStability
TLC Conditions
As Reported
Storage and Stability
May be stored at RT for short-term only. Long-term storage is recommended at 4°C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Light sensitive and hygroscopic.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.
Form
Supplied as a white solid.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
